CCL2 LPMAlternative Names: OPL-CCL2-LPM
Latest Information Update: 22 Mar 2017
At a glance
- Originator Osprey Pharmaceuticals
- Class Chemokines; Proteins
- Mechanism of Action CCR2 receptor antagonists; Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported IgA nephropathy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in IgA-nephropathy in Canada (IV)